Abstract
The incidence of cervical cancer increases with increased age and follicle poietin level. At the same time, the increase in FSH level has a certain predictive value for the incidence of cervical cancer.
Introduction
Cervical cancer remains a leading cause of mortality among women globally. While Human Papillomavirus (HPV) infection is the primary driver, it is not the sole factor; many women with HPV do not develop cancer, suggesting that the body’s internal environment plays a critical role. This study addresses the gap in our understanding of how metabolic and endocrine markers—specifically sex hormones—correlate with cervical health. Identifying systemic biomarkers like hormone levels could help clinicians better predict which patients are at higher risk, especially during the hormonal shifts of perimenopause and menopause.
Methodology and Dataset
The researchers conducted a retrospective correlation study at the Health Management Center of the Affiliated Hospital of Guizhou Medical University. The study initially enrolled over 13,000 participants, eventually narrowing the focus to a primary clinical dataset of 910 female participants recruited between 2019 and 2023.
Participants were divided into "positive" (n=265) and "negative" (n=645) groups based on Thinprep Cytologic Test (TCT) results. Blood samples were collected between the second and fifth day of the menstrual cycle to measure six key hormones: follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), prolactin (PRL), progesterone (P), and testosterone (T).
Key Insights
Analysis revealed a distinct hormonal "fingerprint" associated with cervical risk. Women with positive TCT results showed significantly higher levels of FSH and testosterone, but lower levels of estradiol and prolactin compared to the healthy control group.
Furthermore, the study identified a "metabolic synergy" where positive TCT results correlated with higher systolic blood pressure, fasting blood glucose, and LDL cholesterol. This suggests that metabolic syndrome might create a permissive environment for the development of cervical lesions.
Predictive Performance
A central finding of the research is the predictive power of FSH and age. In clinical diagnostics, an Area Under the Curve (AUC) above 0.7 is generally considered to have acceptable predictive value.
The study found the following performance metrics:
- FSH: AUC of 0.701, with an optimal diagnostic cutoff of 44.625 mIU/mL (67.2% sensitivity, 71.6% specificity).
- Age: AUC of 0.705, with a critical threshold of 50.5 years (58.5% sensitivity, 74.5% specificity).
These results suggest that as women enter menopause and FSH levels naturally rise, the risk of cervical lesions increases, with 50.5 years acting as a significant age threshold for heightened screening.
Limitations and Future Work
The authors acknowledge that this study was limited to a single hospital in Guizhou, China, and its retrospective design identifies correlations rather than direct causation. Future work should involve larger, multi-center prospective studies to validate these findings and explore the prognostic value of hormone levels as the disease progresses or during treatment.
Summary updated